ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Employees: 54
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
115% more capital invested
Capital invested by funds: $29.7M [Q1] → $63.9M (+$34.2M) [Q2]
16% more funds holding
Funds holding: 79 [Q1] → 92 (+13) [Q2]
3.51% more ownership
Funds ownership: 11.04% [Q1] → 14.56% (+3.51%) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
32% less call options, than puts
Call options by funds: $461K | Put options by funds: $675K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
128%
upside
Avg. target
$13.33
176%
upside
High target
$15
211%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio | 211%upside $15 | Buy Maintained | 30 Jul 2025 |
Oppenheimer Jay Olson | 190%upside $14 | Outperform Initiated | 29 Jul 2025 |
Canaccord Genuity Sumant Kulkarni | 128%upside $11 | Buy Maintained | 28 Jul 2025 |
Financial journalist opinion
Based on 6 articles about ATAI published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Positive
Proactive Investors
1 week ago
atai Life Sciences marks milestone quarter with key clinical wins, Beckley merger plans
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has reflected on a “transformational” first half of 2025, marked by a series of clinical and corporate milestones, including positive topline data from its Phase 2b trial of BPL-003 for treatment-resistant depression. The randomized, quadruple-masked global study enrolled 193 patients and met its primary and all key secondary endpoints.
Neutral
Seeking Alpha
4 weeks ago
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus
Despite the phase 2b failure of inidascamine for CIAS, I maintain a Buy on Atai due to its diversified psychedelic pipeline. Beckley Psytech's BPL-003 drug for treatment-resistant depression showed strong phase 2b results, with rapid and sustained efficacy, and could be phase 2 program with FDA allowance. The pending merger with Beckley Psytech and upcoming catalysts, including FDA meetings and OLE study data, offer significant upside potential.
Neutral
Benzinga
4 weeks ago
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.
Neutral
Proactive Investors
4 weeks ago
atai eyes 2025 catalysts in psychedelic portfolio following Recognify trial update
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said on Friday that its platform company, Recognify Life Sciences, reported top-line results from a Phase 2b trial of inidascamine in cognitive impairment associated with schizophrenia (CIAS), which did not meet the primary endpoint but demonstrated consistent signs of cognitive and functional benefit and maintained a favorable safety profile. The double-blind, placebo-controlled study enrolled 242 patients and tested two doses of inidascamine over a six-week treatment period.
Negative
Benzinga
4 weeks ago
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Monday.
Negative
Reuters
1 month ago
Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial
Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schizophrenia.
Neutral
GlobeNewsWire
1 month ago
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.
Positive
Proactive Investors
1 month ago
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and establish a leading position in the treatment-resistant depression (TRD) market with its intranasal 5-MeO-DMT candidate BPL-003. The analysts maintain a ‘Buy' rating and $7 price target on atai, about double the stock's price at the time of writing.
Positive
Proactive Investors
1 month ago
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and establish a leading position in the treatment-resistant depression (TRD) market with its intranasal 5-MeO-DMT candidate BPL-003. The analysts maintain a ‘Buy' rating and $7 price target on atai, about double the stock's price at the time of writing.
Charts implemented using Lightweight Charts™